BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C059I2
Authority: BE; Belgium

Application number

BE2016C059C

Other languages

Dutch (nl)

Original Assignee

Novozymes Biopharma Dk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2016-11-04

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-04 Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As

2020-08-20 Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)

BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (ru)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US19938400P	2000-04-25	2000-04-25
US25693100P	2000-12-21	2000-12-21
EP01934875A EP1278767A4 (en)	2000-04-12	2001-04-12	ALBUMIN FUSED PROTEINS
EP06076852A EP1832599A3 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
EP08075909A EP2067488A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Publications (1)

Publication Number	Publication Date
BE2016C059I2 true BE2016C059I2 (ru)	2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C059C BE2016C059I2 (ru)	2000-04-12	2016-11-04

Country Status (10)

Country	Link
US (23)	US20040010134A1 (ru)
EP (21)	EP2295456A1 (ru)
JP (9)	JP2003530839A (ru)
AU (7)	AU2001261024A1 (ru)
BE (1)	BE2016C059I2 (ru)
CA (8)	CA2405701A1 (ru)
DK (2)	DK2236152T3 (ru)
ES (2)	ES2529300T3 (ru)
FR (1)	FR16C0043I2 (ru)
WO (7)	WO2001077137A1 (ru)

Families Citing this family (668)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2002068638A1 (en) *	2001-02-23	2002-09-06	Human Genome Sciences, Inc.	83 human secreted proteins
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (de) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Humanes und murines Semaphorin L
US20030166110A1 (en) *	1997-09-18	2003-09-04	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
CA2330527A1 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corporation	Erythropoietin analog-human serum albumin fusion
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
EP1121425B1 (en)	1998-10-13	2005-06-29	The University Of Georgia Research Foundation, Inc.	Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001077137A1 (en)	2000-04-12	2001-10-18	Human Genome Sciences, Inc.	Albumin fusion proteins
DE60026695T2 (de) *	1999-05-05	2006-11-02	Phylogica Ltd., Northbridge	ISOLIERUNG VON BIOLOGISCHEN MODULATOREN AUS BIBIOTHEKEN MIT BIOLOGISCH VIELFäLTIGEN GENFRAGMENTEN
US6946129B1 (en) *	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
CA2388822A1 (en) *	1999-10-29	2001-05-10	Human Genome Sciences, Inc.	27 human secreted proteins
AU1449001A (en) *	1999-11-05	2001-06-06	Human Genome Sciences, Inc.	28 human secreted proteins
AU1578901A (en) *	1999-11-05	2001-06-06	Human Genome Sciences, Inc.	24 human secreted proteins
AU1472701A (en) *	1999-11-12	2001-06-06	Human Genome Sciences, Inc.	28 human secreted proteins
CA3016482A1 (en)	1999-11-30	2001-06-07	Mayo Foundation For Medical Education And Research	B7-h1, a novel immunoregulatory molecule
AU784285B2 (en)	1999-12-24	2006-03-02	Genentech Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
WO2001085936A1 (en) *	2000-05-12	2001-11-15	Merck Patent Gmbh	F-box containing protein
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
AU2001274923A1 (en) *	2000-05-23	2001-12-03	Lexicon Genetics Incorporated	Novel human thrombospondin-like proteins and polynucleotides encoding the same
CA2412377A1 (en)	2000-06-06	2001-12-13	Bristol-Myers Squibb Company	B7-related nucleic acids and polypeptides and their uses for immunomodulation
CA2409392A1 (en) *	2000-06-08	2001-12-13	Incyte Genomics, Inc.	Intracellular signaling proteins
CA2414228A1 (en) *	2000-06-21	2001-12-27	Amgen, Inc.	Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
CA2418676A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	21 human secreted proteins
EP1317468A4 (en) *	2000-08-18	2004-07-07	Human Genome Sciences Inc	23 HUMAN SECRETED PROTEINS
CA2418680A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	11 human secreted proteins
CA2420902A1 (en) *	2000-08-28	2002-03-07	Craig A. Rosen	18 human secreted proteins
EP1322659A4 (en) *	2000-09-20	2005-01-26	Human Genome Sciences Inc	21 HUMANE SECRET PROTEINS
AU2001227920A1 (en) *	2000-09-29	2002-04-15	Human Genome Sciences, Inc.	24 human secreted proteins
CA2425827A1 (en) *	2000-10-12	2002-04-18	Hyseq, Inc.	Novel nucleic acids and polypeptides
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (fr) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7074913B2 (en)	2000-12-05	2006-07-11	Wisconsin Alumni Research Foundation	Receptor for B anthracis toxin
BR0116024A (pt)	2000-12-07	2005-12-13	Lilly Co Eli	Proteìna de fusão heteróloga e uso da mesma
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
EP1354950A4 (en) *	2000-12-28	2005-01-12	Asahi Kasei Pharma Corp	ACTIVATION GENE OF NF-KB
WO2002072138A1 (en) *	2001-03-08	2002-09-19	Hyseq, Inc.	Methods and materials relating to fibulin-like polypeptides and polynucleotides
WO2002083921A2 (en)	2001-04-10	2002-10-24	Agensys, Inc.	Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20030100497A1 (en)	2001-06-20	2003-05-29	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2002328853A1 (en) *	2001-07-06	2003-01-21	Geneprot, Inc.	Carcinoma-related peptides
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
WO2003030821A2 (en) *	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10251673A1 (de)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
KR100406760B1 (ko) *	2001-11-16	2003-11-21	신코엠 주식회사	반도체 메모리 장치
ES2320743T3 (es)	2001-12-17	2009-05-28	Laboratoires Serono Sa	Mutantes de quimiocina que actuan como antagonistas de quimiocinas.
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
EP2277889B1 (en) *	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
CA2484556A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
KR20040095217A (ko) *	2002-02-07	2004-11-12	델타 바이오테크놀로지 리미티드	알부민-융합 항-혈관신생 펩타이드
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
DE10205520A1 (de) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
PL374966A1 (en) *	2002-02-21	2005-11-14	Wyeth	Follistatin domain containing proteins
CA2477614A1 (en) *	2002-03-05	2003-09-18	Merck & Co., Inc.	Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003225008A1 (en) *	2002-04-15	2003-11-03	American National Red Cross	Plasma protein-binding ligands
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
EP1490108A4 (en)	2002-04-18	2006-08-09	Gen Hospital Corp	DRAG11 GENERAL FAMILY (DRAGON)
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en)	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
ES2348230T3 (es)	2002-06-07	2010-12-01	Dyax Corp.	Prevención y reducción de la isquemia.
EP2380633A1 (en) *	2002-06-07	2011-10-26	ZymoGenetics, Inc.	Use of IL-21 in cancer
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN101172091B (zh) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2004005520A1 (en) *	2002-07-03	2004-01-15	Nexgen Biotechnologies, Inc.	Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
AU2003247806B2 (en) *	2002-07-08	2009-11-12	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
CA2493263A1 (en) *	2002-07-22	2004-01-29	Yamanouchi Pharmaceutical Co., Ltd.	Novel gene associated with rheumatoid arthritis
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
KR20050065519A (ko) *	2002-08-07	2005-06-29	델타 바이오테크놀로지 리미티드	알부민-융합 섬모 신경영양 인자
KR20050083627A (ko) *	2002-08-13	2005-08-26	아비오스 테크놀러지스 인코포레이티드	선택적 혈장 교환 치료
PT2386310T (pt)	2002-08-28	2019-02-05	Dyax Corp	Métodos para preservar órgãos e tecidos
WO2004022096A1 (en) *	2002-09-06	2004-03-18	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
US20060128615A1 (en) *	2002-09-18	2006-06-15	Pierrette Gaudreau	Ghrh analogues
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ATE401346T1 (de) *	2002-12-20	2008-08-15	Geneos Oy	Asthma-empfindlichkeitsort
AU2003292774A1 (en) *	2002-12-26	2004-07-22	Takeda Pharmaceutical Company Limited	Novel proteins and use thereof
EP1594530A4 (en) *	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
EP2325302B1 (en) *	2003-02-11	2016-01-06	Shire Human Genetic Therapies, Inc.	Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
EP1605961A4 (en) *	2003-03-12	2009-11-11	Vasgene Therapeutics Inc	POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082640A2 (en) *	2003-03-19	2004-09-30	New Century Pharmaceuticals, Inc.	Human serum albumin conjugates with therapeutic compounds
CN1798770B (zh) *	2003-04-04	2010-06-09	洛桑大学	用于治疗癌症的多聚肽体
WO2004091510A2 (en)	2003-04-11	2004-10-28	Medimmune, Inc.	Recombinant il-9 antibodies and uses thereof
WO2004094589A2 (en) *	2003-04-18	2004-11-04	Incyte Corporation	Secreted proteins
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP4817233B2 (ja) *	2003-06-30	2011-11-16	学校法人日本大学	細胞外基質沈着タンパク質
AU2004259727A1 (en)	2003-07-15	2005-02-03	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases.
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
EP1694360B1 (en)	2003-11-04	2010-08-04	Novartis Vaccines and Diagnostics, Inc.	Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
US20080292581A1 (en) *	2003-12-03	2008-11-27	Delta Biotechnology Limited	Interleukin-11 Fusion Proteins
CN100379762C (zh) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
US7371381B2 (en)	2003-12-12	2008-05-13	Amgen Inc.	Anti-galanin antibodies and uses thereof
WO2006067511A1 (en)	2004-12-23	2006-06-29	Novozymes Delta Limited	Gene expression technique
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
WO2005061704A1 (ja) *	2003-12-24	2005-07-07	Takeda Pharmaceutical Company Limited	癌の予防・治療剤
CA2554089C (en) *	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
SE0400489D0 (sv) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
DE602005019540D1 (de) *	2004-03-03	2010-04-08	Evotec Neurosciences Gmbh	Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
EP1740047A2 (en) *	2004-03-11	2007-01-10	Kythera Biopharmaceuticals, Inc.	Compositions and methods for preventing and treating skin and hair conditions
ATE492564T1 (de)	2004-03-12	2011-01-15	Vasgene Therapeutics Inc	Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
EP1734991A4 (en)	2004-04-14	2012-10-24	Avirid Inc	COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
PT2100904E (pt) *	2004-04-23	2010-09-24	Conjuchem Biotechnologies Inc	Fase sólida para utilização num método para a purificação de conjugados de albumina
KR100599454B1 (ko) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	종양 억제자로 작용하는 ａｉｍ3의 신규 용도
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2568976A1 (en) *	2004-06-03	2005-12-22	Ciphergen Biosystems, Inc.	Biomarkers for peripheral artery disease
EP1768647B1 (en) *	2004-06-17	2012-08-08	Virun, Inc.	Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent
EP1773375A1 (en)	2004-07-14	2007-04-18	University of Utah Research Foundation	Netrin-related compositions and uses
WO2006028655A2 (en) *	2004-08-13	2006-03-16	Millennium Pharmaceuticals, Inc.	Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
CA2580921C (en)	2004-09-21	2016-04-12	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP1799713B1 (en) *	2004-09-23	2014-11-05	VasGene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006039504A2 (en) *	2004-10-01	2006-04-13	Cell Ionix, Inc.	Method and formulation for stem cells’ stimulation
MX2007004176A (es)	2004-10-06	2007-06-15	Mayo Foundation	B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
WO2006042197A2 (en) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Use of del-1 in hair, bone and cartilage regeneration
US8071716B2 (en) *	2004-10-25	2011-12-06	Immune System Key Ltd.	Thymus-specific protein
KR100583350B1 (ko) *	2004-11-03	2006-06-05	(주)넥스젠	Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
MX2007005327A (es) *	2004-11-09	2007-08-02	Ares Trading Sa	Metodo para purificacion de la hormona foliculo estimulante (hfe).
US20090196850A1 (en)	2005-01-06	2009-08-06	Novo Nordisk A/S	Anti-Kir Combination Treatments and Methods
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
KR101289537B1 (ko)	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
BRPI0609439A2 (pt) *	2005-03-23	2010-04-06	Wyeth Corp	detecção de uma resposta imunológica a agentes moduladores de gdf-8
WO2006102574A2 (en) *	2005-03-23	2006-09-28	Wyeth	Detection of gdf-8 modulating agents
WO2006111524A2 (en)	2005-04-18	2006-10-26	Novo Nordisk A/S	Il-21 variants
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
EP1874821B1 (de)	2005-04-26	2013-04-17	Trion Pharma Gmbh	Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
US9345745B2 (en) *	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en) *	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
EP1885755A4 (en)	2005-05-05	2009-07-29	Univ Duke	CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
JP2008546426A (ja) *	2005-05-12	2008-12-25	ザイモジェネティクス，インコーポレイテッド	Ｔ細胞を共刺激するためにｐＨＨＬＡ２を使用する方法
DK1907000T4 (da)	2005-06-08	2020-03-30	The President And Fellows Of Harvard College	Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
WO2007014167A2 (en) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
DK2573114T3 (en)	2005-08-10	2016-07-04	Macrogenics Inc	The identification and production of antibodies with variant Fc regions, and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
JP4944112B2 (ja)	2005-08-26	2012-05-30	アレストレーディングソシエテアノニム	グリコシル化されたインターフェロンベータの調製方法
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
JP2009509535A (ja) *	2005-09-27	2009-03-12	アムニクス，インコーポレイテッド	タンパク様薬剤およびその使用
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US20080274096A1 (en) *	2005-10-03	2008-11-06	Astrazeneca Ab	Fusion Proteins Having a Modulated Half-Life in Plasma
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
EP1960419B1 (en) *	2005-12-09	2016-03-16	Ares Trading S.A.	Method for purifying fsh or a fsh mutant
WO2007075326A2 (en) *	2005-12-09	2007-07-05	Seattle Genetics, Inc.	Methods of using cd40 binding agents
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
JP2009520469A (ja) *	2005-12-22	2009-05-28	コンジュクヘムビオテクフノロギエスインコーポレイテッド	アルブミンと治療薬との前もって形成された抱合体の産生のための方法
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
AU2007207544A1 (en)	2006-01-17	2007-07-26	Health Research, Inc.	Heteroduplex tracking assay
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
US20070248646A1 (en) *	2006-02-16	2007-10-25	Ali Hafezi-Moghadam	Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2540741A1 (en)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
SG170837A1 (en)	2006-04-05	2011-05-30	Abbott Biotech Ltd	Antibody purification
DE602007007923D1 (de) *	2006-04-11	2010-09-02	Csl Behring Gmbh	Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
WO2007146038A2 (en) *	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (en) *	2006-06-14	2007-12-19	CSL Behring GmbH	Proteolytically cleavable fusion protein comprising a blood coagulation factor
ES2910207T3 (es) *	2006-06-14	2022-05-11	Csl Behring Gmbh	Proteínas de fusión escindibles proteolíticamente que comprenden un factor de coagulación de la sangre
KR101507021B1 (ko) *	2006-07-13	2015-03-30	업퍼톤 리미티드	단백질성 물질의 입자를 제조하기 위한 방법
CA2658654A1 (en)	2006-07-24	2008-01-31	Biorexis Pharmaceutical Corporation	Exendin fusion proteins
AU2007281998B2 (en) *	2006-08-04	2014-02-20	Pharmathene Inc.	Long half-life recombinant butyrylcholinesterase
CN101578373A (zh) *	2006-09-06	2009-11-11	费斯生物制药公司	融合肽治疗组合物
CA2663083A1 (en)	2006-09-08	2008-03-13	Ambrx, Inc.	Modified human plasma polypeptide or fc scaffolds and their uses
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7820623B2 (en)	2006-10-25	2010-10-26	Amgen Inc.	Conjugated toxin peptide therapeutic agents
EP2091968A2 (en)	2006-10-26	2009-08-26	Novo Nordisk A/S	Il-21 variants
JP5588175B2 (ja)	2006-11-07	2014-09-10	メルク・シャープ・アンド・ドーム・コーポレーション	Ｐｃｓｋ９のアンタゴニスト
KR20090098880A (ko)	2006-12-12	2009-09-17	바이오렉시스 파마슈티칼 코포레이션	트랜스페린 융합 단백질 라이브러리
EP2514767A1 (en)	2006-12-19	2012-10-24	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2557090A3 (en)	2006-12-19	2013-05-29	Ablynx N.V.	Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP1935430A1 (en) *	2006-12-22	2008-06-25	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
EP2097096B1 (en)	2006-12-22	2017-05-31	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
CN107011431B (zh)	2007-01-30	2020-11-06	埃皮瓦克斯公司	调节性t细胞表位、组合物及其用途
CA2678001C (en)	2007-02-12	2017-07-11	Stefan Schulte	Therapeutic application of kazal-type serine protease inhibitors
CA2680832A1 (en)	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
US20080279851A1 (en)	2007-05-07	2008-11-13	Medlmmune, Llc	Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2685222C (en)	2007-05-14	2017-12-19	Medimmune, Llc	Methods of reducing eosinophil levels
AU2008262490B2 (en)	2007-05-22	2011-11-17	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
CA2693707A1 (en)	2007-07-13	2009-03-05	The Johns Hopkins University	B7-dc variants
WO2009012502A1 (en) *	2007-07-19	2009-01-22	The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University	Self- anchoring mems intrafascicular neural electrode
CN103298935A (zh) *	2007-08-15	2013-09-11	阿穆尼克斯公司	用于改善生物活性多肽性能的组合物和方法
MX2010001975A (es)	2007-08-29	2010-03-10	Sanofi Aventis	Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
JP2009055838A (ja) *	2007-08-31	2009-03-19	Nipro Corp	融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
EP2853267B1 (en) *	2007-09-21	2016-12-07	The Regents of the University of California	Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
CA2702448A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying fc-fusion proteins
CA2701221A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying an fc-containing protein
US9308257B2 (en)	2007-11-28	2016-04-12	Medimmune, Llc	Protein formulation
EP2245064B1 (en)	2007-12-21	2014-07-23	Medimmune Limited	BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20100311072A1 (en) *	2008-01-28	2010-12-09	Bristol-Myers Squibb Company	Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
JP5020135B2 (ja) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	携帯端末装置およびコンピュータプログラム
ES2563553T3 (es)	2008-04-01	2016-03-15	Novo Nordisk A/S	Conjugados de insulina-albúmina
CN102056945A (zh)	2008-04-07	2011-05-11	埃博灵克斯股份有限公司	针对Notch途径的单可变结构域
PT2274331E (pt)	2008-05-02	2014-02-27	Novartis Ag	Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
KR101648734B1 (ko)	2008-06-24	2016-08-18	체에스엘 베링 게엠베하	연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
WO2009158704A2 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
CN102149379A (zh)	2008-07-10	2011-08-10	安吉翁生物医药有限公司	调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
EP2313436B1 (en)	2008-07-22	2014-11-26	Ablynx N.V.	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
ES2643411T3 (es)	2008-08-05	2017-11-22	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a la proteína del complemento C5
EP2328919A2 (en) *	2008-08-25	2011-06-08	Amplimmune, Inc.	Pd-i antagonists and methods for treating infectious disease
PL2350129T3 (pl)	2008-08-25	2015-12-31	Amplimmune Inc	Kompozycje antagonistów PD-1 i sposoby stosowania
BRPI0823049A2 (pt)	2008-09-07	2015-06-16	Glyconex Inc	Anticorpos para glicoesfingolipídeos tipo 1 anti-estendidos, derivados dos mesmos e uso.
CN102438652B (zh)	2008-11-12	2014-08-13	米迪缪尼有限公司	抗体制剂
JP5677972B2 (ja)	2008-11-18	2015-02-25	メリマックファーマシューティカルズインコーポレーティッド	ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP2370593B1 (en)	2008-11-28	2016-03-30	Emory University	Methods for determining the efficacy of pd-1 antagonists
EP4331604B9 (en)	2008-12-09	2025-07-23	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
JP2012515222A (ja)	2009-01-16	2012-07-05	テバファーマシューティカルインダストリーズリミテッド	組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
EA020843B1 (ru)	2009-02-03	2015-02-27	Амуникс Оперейтинг Инк.	Удлиненные рекомбинантные полипептиды и содержащие их композиции
US8716448B2 (en) *	2009-02-03	2014-05-06	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
ES2630253T3 (es)	2009-02-11	2017-08-18	Albumedix A/S	Variantes de albúmina y conjugados
WO2010108154A2 (en)	2009-03-20	2010-09-23	Amgen Inc.	Selective and potent peptide inhibitors of kv1.3
EP2427486B1 (en)	2009-05-07	2015-02-25	Novozymes Biopharma DK A/S	Method for purifying albumin
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
WO2010138555A2 (en) *	2009-05-26	2010-12-02	University Of Florida Research Foundation, Inc.	Small peptide expression system in mammalian cells
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
ES2705249T3 (es)	2009-06-08	2019-03-22	Amunix Operating Inc	Polipéptidos reguladores de glucosa y métodos para su producción y uso
JP5883384B2 (ja)	2009-08-13	2016-03-15	ザジョンズホプキンスユニバーシティー	免疫機能を調節する方法
WO2011020866A2 (en)	2009-08-20	2011-02-24	Csl Behring Gmbh	Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
UY32917A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moléculas de unión a dll-4
UY32920A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
PL2486141T3 (pl)	2009-10-07	2018-07-31	Macrogenics, Inc.	Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
WO2011051278A1 (en) *	2009-10-26	2011-05-05	Externautics S.P.A.	Lung tumor markers and methods of use thereof
IN2012DN03824A (ru)	2009-10-30	2015-08-28	Merck Sharp & Dohme
US8748380B2 (en)	2009-10-30	2014-06-10	Novozymes Biopharma Dk A/S	Albumin variants
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
CN102596249A (zh)	2009-10-30	2012-07-18	默沙东公司	Ax1和ax189 pcsk9拮抗剂和变体
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011060528A1 (en) *	2009-11-17	2011-05-26	Universite De Montreal	Heteropeptides useful for reducing nonspecific adsorption
PT3326643T (pt)	2009-12-06	2021-07-12	Bioverativ Therapeutics Inc	Polipéptidos quiméricos e híbridos de fator viii-fc e métodos para a sua utilização
EP2509616A4 (en)	2009-12-08	2013-05-29	Teva Pharma	BCHE-ALBUMIN FUSION PROTEINS FOR THE TREATMENT OF COCAINOMANIA
US8962807B2 (en)	2009-12-14	2015-02-24	Ablynx N.V.	Single variable domain antibodies against OX40L, constructs and therapeutic use
AU2010340358B2 (en)	2009-12-21	2014-07-24	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
RS62853B1 (sr)	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
AR079944A1 (es)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
US9211342B2 (en)	2010-01-22	2015-12-15	Novo Nordisk Healthcare Ag	Stable growth hormone compounds resistant to proteolytic degradation
KR101813595B1 (ko)	2010-01-22	2017-12-29	노보 노르디스크 헬스 케어 악티엔게젤샤프트	장기적 생체 내 효능을 갖는 성장 호르몬
WO2011092233A1 (en)	2010-01-29	2011-08-04	Novartis Ag	Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
US8592364B2 (en) *	2010-02-11	2013-11-26	Ecole Polytechnique Federale de Lausanne (“EPFL”)	CCR7 ligand delivery and co-delivery in immunotherapy
CA2788275A1 (en)	2010-03-03	2011-09-09	Boehringer Ingelheim International Gmbh	Biparatopic abeta binding polypeptides
EP2371857A1 (en)	2010-04-01	2011-10-05	CSL Behring GmbH	Factor XII inhibitors for treating interstitial lung disease
US10233228B2 (en)	2010-04-09	2019-03-19	Albumedix Ltd	Albumin derivatives and variants
CA2798390A1 (en)	2010-05-06	2011-11-10	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en)	2010-05-06	2017-12-20	Novartis AG	Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
EP3546483A1 (en)	2010-05-20	2019-10-02	Ablynx N.V.	Biological materials related to her3
CN103140237A (zh)	2010-07-09	2013-06-05	比奥根艾迪克依蒙菲利亚公司	因子ix多肽及其使用方法
WO2012006623A1 (en)	2010-07-09	2012-01-12	Biogen Idec Hemophilia Inc.	Systems for factor viii processing and methods thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
EP2603520A4 (en)	2010-08-10	2014-02-19	Ecole Polytech	ERYTHROCYTE BINDING THERAPEUTICS
PL2606070T3 (pl)	2010-08-20	2017-06-30	Novartis Ag	Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
SG10201506782XA (en)	2010-08-27	2015-10-29	Stem Centrx Inc	Notum protein modulators and methods of use
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
JP6327855B2 (ja)	2010-09-03	2018-05-23	アッヴィ・ステムセントルクス・エル・エル・シー	新規モジュレータ及びその使用法
EP2619226B1 (en)	2010-09-22	2018-09-12	Amgen Inc.	Carrier immunoglobulins and uses thereof
JP6174489B2 (ja)	2010-09-28	2017-08-02	アエゲリオンファーマシューティカルズ，インコーポレイテッド	高可溶性レプチン
CN104531812A (zh)	2010-10-01	2015-04-22	现代治疗公司	设计核酸及其使用方法
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
WO2012059486A1 (en)	2010-11-01	2012-05-10	Novozymes Biopharma Dk A/S	Albumin variants
AU2011325833C1 (en)	2010-11-05	2017-07-13	Zymeworks Bc Inc.	Stable heterodimeric antibody design with mutations in the Fc domain
CU24111B1 (es)	2010-11-08	2015-08-27	Novartis Ag	Polipéptidos que se enlazan a cxcr2
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
WO2012069466A1 (en)	2010-11-24	2012-05-31	Novartis Ag	Multispecific molecules
CA2820885A1 (en)	2010-12-08	2012-09-07	Stem Centrx, Inc.	Novel modulators and methods of use
ES2689753T3 (es)	2010-12-28	2018-11-15	Sumitomo Dainippon Pharma Co., Ltd	Fármaco de diagnóstico y método de diagnóstico para la enfermedad de Alzheimer
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
CN103635489B (zh)	2011-01-06	2016-04-13	戴埃克斯有限公司	血浆前激肽释放酶结合蛋白
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
US20140105898A1 (en)	2011-02-28	2014-04-17	Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo	Apoptosis-inducing molecules and uses therefor
ES2676878T3 (es)	2011-03-03	2018-07-25	Zymeworks Inc.	Diseño de armazón de heteromultímero multivalente y constructos
EP2497489A1 (en)	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN103415301A (zh)	2011-03-09	2013-11-27	德国杰特贝林生物制品有限公司	用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
TWI700093B (zh)	2011-03-16	2020-08-01	法商賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
AU2012228990B2 (en)	2011-03-16	2017-04-06	Amgen Inc.	Potent and selective inhibitors of Nav1.3 and Nav1.7
WO2012135500A1 (en)	2011-03-29	2012-10-04	The General Hospital Corporation	Engineered thioredoxin-like fold proteins
BR112013025031A2 (pt)	2011-03-30	2017-08-01	Boehringer Ingelheim Int	antídotos anticoagulantes
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
SG10201603034TA (en)	2011-04-15	2016-05-30	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) *	2011-04-22	2015-08-12	Sysmex Corporation	Method for electrochemically detecting analyte
WO2012149197A2 (en)	2011-04-27	2012-11-01	Abbott Laboratories	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104011072B (zh)	2011-05-05	2018-10-12	阿尔布梅迪克斯医疗有限公司	白蛋白变体
WO2012170740A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
CA2838833A1 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR20220003656A (ko) *	2011-06-28	2022-01-10	인히브릭스, 인크.	세르핀 융합 폴리펩타이드 및 이의 이용 방법
MX2014000031A (es)	2011-07-01	2014-07-09	Bayer Ip Gmbh	Polipeptidos de fusion de relaxina y usos de los mismos.
US10844349B2 (en)	2011-07-05	2020-11-24	Albumedix Ltd.	Albumin formulation and use
DK2729160T3 (da)	2011-07-08	2019-07-01	Aegerion Pharmaceuticals Inc	Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
EP2729494A1 (en)	2011-07-08	2014-05-14	Bayer Intellectual Property GmbH	Fusion proteins releasing relaxin and uses thereof
WO2013010840A2 (en) *	2011-07-18	2013-01-24	Arts Biologics A/S	Long acting biologically active luteinizing hormone (lh) compound
FI2734552T3 (fi)	2011-07-22	2025-02-12	Csl Behring Gmbh	Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt)	2011-10-03	2021-11-03	Moderna Therapeutics, Inc	Polinucleotídeo isolado modificado e composição farmacêutica
WO2013067055A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Methods of blocking cancer stem cell growth
AU2012332590B2 (en)	2011-11-01	2016-10-20	Bionomics, Inc.	Anti-GPR49 antibodies
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
WO2013067060A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
US9221906B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of inhibiting solid tumor growth by administering GPR49 antibodies
AU2012332021B8 (en)	2011-11-04	2017-10-12	Zymeworks Bc Inc.	Stable heterodimeric antibody design with mutations in the Fc domain
EP3252075A1 (en)	2011-11-04	2017-12-06	Novartis AG	Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
EP2780364A2 (en)	2011-11-18	2014-09-24	Eleven Biotherapeutics, Inc.	Proteins with improved half-life and other properties
SG11201402783YA (en)	2011-12-05	2014-06-27	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
BR112014013568A2 (pt)	2011-12-05	2017-06-13	Novartis Ag	anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
PL2791160T3 (pl)	2011-12-16	2022-06-20	Modernatx, Inc.	Kompozycje zmodyfikowanego mrna
SG10201703249PA (en)	2011-12-21	2017-05-30	Novartis Ag	Compositions and methods for antibodies targeting factor p
JP6127063B2 (ja)	2011-12-22	2017-05-10	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US11370827B2 (en)	2012-01-12	2022-06-28	Bioverativ Therapeutics Inc.	Chimeric factor VIII polypeptides and uses thereof
EP2623110A1 (en)	2012-01-31	2013-08-07	CSL Behring GmbH	Factor XII inhibitors for the treatment of neurological inflammatory disorders
DK2814502T3 (en) *	2012-02-15	2017-12-18	Csl Behring Gmbh	Von Willebrand Factor variants with improved Factor VIII binding affinity
EP2822577B1 (en)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
PT3564260T (pt)	2012-02-15	2023-01-18	Bioverativ Therapeutics Inc	Composições de fator viii e métodos de produção e utilização das mesmas
KR20150010699A (ko)	2012-02-15	2015-01-28	에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘)	적혈구 결합요법
JP6089047B2 (ja)	2012-02-24	2017-03-01	アッヴィ・ステムセントルクス・エル・エル・シー	Ｄｌｌ３モジュレーター及び使用方法
PH12021553014A1 (en)	2012-02-27	2022-09-05	Ablynx Nv	Cx3cr1-binding polypeptides
ES2664328T3 (es)	2012-03-16	2018-04-19	Albumedix A/S	Variantes de albúmina
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
US9550819B2 (en)	2012-03-27	2017-01-24	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
HK1206779A1 (en)	2012-04-02	2016-01-15	Modernatx, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
CN104540518A (zh)	2012-04-27	2015-04-22	西托姆克斯治疗公司	结合表皮生长因子受体的可活化的抗体其使用方法
WO2013166290A1 (en)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	P21 biomarker assay
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
WO2013166594A1 (en)	2012-05-10	2013-11-14	Zymeworks Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
PL2854547T3 (pl)	2012-05-30	2019-02-28	Bayer Cropscience Ag	Kompozycja zawierająca środek kontroli biologicznej i trifloksystrobinę
KR102095976B1 (ko)	2012-05-30	2020-04-02	바이엘 크롭사이언스 악티엔게젤샤프트	생물학적 방제제 및 살곤충제를 포함하는 조성물
WO2013178656A1 (en)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide
IN2014DN09513A (ru)	2012-05-30	2015-07-17	Bayer Cropscience Ag
MX355541B (es)	2012-05-30	2018-04-20	Bayer Cropscience Ag	Composicion que comprende un agente de control biologico y un fungicida inhibidores de la sintesis de membrana lipidica, inhibidores de la biosintesis de melanina, inhibidores de la sintesis de acidos nucleicos, inhibidores de la transduccion de señales.
WO2013178649A1 (en)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex i or ii.
BR112014029906A2 (pt)	2012-05-30	2018-04-17	Bayer Cropscience Ag	composições compreendendo um agente de controle biológico e um inseticida.
KR20150021539A (ko)	2012-05-30	2015-03-02	바이엘 크롭사이언스 아게	생물학적 방제제, 및 유사분열 및 세포 분열의 억제제 또는 다중부위 작용을 갖는 화합물로부터 선택된 살진균제를 포함하는 조성물
US9380787B2 (en)	2012-05-30	2016-07-05	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of amino acid or protein biosynthesis, inhibitors of ATP production and inhibitors of the cell wall synthesis
CN104470359B (zh)	2012-05-30	2017-05-24	拜尔农作物科学股份公司	包括一种生物防治剂和一种杀虫剂的组合物
NZ701496A (en)	2012-05-30	2016-11-25	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
CN104507311A (zh)	2012-05-30	2015-04-08	拜尔农作物科学股份公司	包含生物防治剂和杀虫剂的组合物
CA2875247A1 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Chimeric clotting factors
AU2013270682A1 (en)	2012-06-08	2014-12-11	Biogen Ma Inc.	Procoagulant compounds
KR101380740B1 (ko)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	이듀로네이트-2-설파타제의 정제
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN110054699A (zh)	2012-07-11	2019-07-26	比奥贝拉蒂治疗公司	具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CA2878640C (en)	2012-07-13	2023-10-24	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
EP2890782A1 (en)	2012-09-02	2015-07-08	AbbVie Inc.	Methods to control protein heterogeneity
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
US10391152B2 (en)	2012-10-18	2019-08-27	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
BR112015010318A2 (pt)	2012-11-08	2017-08-22	Albumedix As	Variantes de albumina
NZ746691A (en)	2012-11-13	2020-08-28	Astellas Pharma Inc	Agents for treatment of claudin expressing cancer diseases
DK2922554T3 (en)	2012-11-26	2022-05-23	Modernatx Inc	Terminalt modificeret rna
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
AU2013355414B2 (en)	2012-12-05	2017-02-02	Novartis Ag	Compositions and methods for antibodies targeting EPO
WO2014099984A1 (en)	2012-12-20	2014-06-26	Amgen Inc.	Apj receptor agonists and uses thereof
CA2896793A1 (en)	2013-01-15	2014-07-24	Teva Pharmaceutical Industries Ltd.	Formulations of albu-bche, preparation and uses thereof
KR101503907B1 (ko) *	2013-01-17	2015-03-20	서울대학교산학협력단	흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
CA2899170C (en)	2013-01-30	2022-08-02	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use in treating metabolic disorders
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
MX2015010259A (es)	2013-02-11	2015-10-29	Bayer Cropscience Lp	Composiciones que comprenden un agente de control biologico basado en la cepa nrrl b-50550 de streptomyces microflavus y otro agente de control biologico.
RS64664B1 (sr)	2013-02-15	2023-11-30	Bioverativ Therapeutics Inc	Gen optimizovanog faktora viii
KR20150118123A (ko)	2013-02-16	2015-10-21	노보자임스 바이오파마 디케이 에이/에스	약동학적 동물 모델
DK2961422T3 (en)	2013-02-28	2017-01-16	Csl Behring Gmbh	Therapeutic agent for amniotic fluid embolism
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
WO2014135694A1 (en)	2013-03-08	2014-09-12	Csl Behring Ag	Treatment and prevention of remote ischemia-reperfusion injury
US10981961B2 (en)	2013-03-11	2021-04-20	University Of Florida Research Foundation, Incorporated	Delivery of card protein as therapy for occular inflammation
EP2830651A4 (en)	2013-03-12	2015-09-02	Abbvie Inc	HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
UY35397A (es)	2013-03-12	2014-10-31	Amgen Inc	INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
EP2968391A1 (en) *	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
EP2968587A2 (en)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3611189A1 (en)	2013-03-14	2020-02-19	Novartis AG	Antibodies against notch 3
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10588949B2 (en)	2013-03-15	2020-03-17	Bioverativ Therapeutics Inc.	Factor IX polypeptide formulations
CA2897334A1 (en)	2013-03-29	2014-10-02	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
EP2796145B1 (en)	2013-04-22	2017-11-01	CSL Ltd.	A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
WO2014207199A1 (en)	2013-06-28	2014-12-31	Csl Behring Gmbh	Combination therapy using a factor xii inhibitor and a c1-inhibitor
CN105392495A (zh)	2013-06-28	2016-03-09	比奥根Ma公司	具有xten的凝血酶可裂解连接子和其用途
CN104342420B (zh) *	2013-07-30	2017-09-15	惠觅宙	一种重组长效人透明质酸酶、其编码基因、生产方法及应用
TW202003554A (zh)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP4108254A1 (en)	2013-08-14	2022-12-28	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
US9387151B2 (en)	2013-08-20	2016-07-12	Anutra Medical, Inc.	Syringe fill system and method
JP2016538318A (ja)	2013-08-28	2016-12-08	ステムセントリックス，インコーポレイテッド	新規ｓｅｚ６モジュレーターおよび使用方法
EP3892294A1 (en)	2013-08-28	2021-10-13	AbbVie Stemcentrx LLC	Site-specific antibody conjugation methods and compositions
HUE057005T2 (hu)	2013-09-25	2022-04-28	Bioverativ Therapeutics Inc	Oszlopon történõ vírusinaktiváló eljárások
CN103468662A (zh) *	2013-09-29	2013-12-25	惠觅宙	一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
US10259875B2 (en)	2013-10-01	2019-04-16	Mayo Foundation For Medical Education And Research	Methods for treating cancer in patients with elevated levels of BIM
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions and methods for treatment of inflammatory bowel disease
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9540440B2 (en)	2013-10-30	2017-01-10	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015066550A1 (en)	2013-10-31	2015-05-07	Resolve Therapeutics, Llc	Therapeutic nuclease-albumin fusions and methods
JP6306700B2 (ja) *	2013-11-01	2018-04-04	ユニバーシティオブオスロＵｎｉｖｅｒｓｉｔｙｏｆＯｓｌｏ	アルブミン改変体及びその使用
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
WO2015073884A2 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
US9737623B2 (en)	2013-12-11	2017-08-22	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP4101461A1 (en)	2014-01-09	2022-12-14	Hadasit Medical Research Services and Development Ltd.	Improved cell compositions and methods for cancer therapy
DK3091997T5 (da)	2014-01-10	2024-10-14	Bioverativ Therapeutics Inc	Kimære faktor viii-proteiner og anvendelser deraf
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
EP3107563B1 (en)	2014-02-21	2021-04-07	Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
EP3116898B1 (en)	2014-03-11	2022-01-26	University of Florida Research Foundation, Inc.	Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
WO2015140591A1 (en)	2014-03-21	2015-09-24	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
MX2016014306A (es)	2014-05-02	2017-06-12	Cerenis Therapeutics Holding Sa	Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (zh) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	一种融合蛋白、其制备方法及其应用
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
WO2015191781A2 (en)	2014-06-10	2015-12-17	Amgen Inc.	Apelin polypeptides
KR102513050B1 (ko)	2014-06-18	2023-03-29	체에스엘 베링 게엠베하	신경외상성 장애에서의 인자 xii 억제제를 이용한 치료요법
EP3157947A1 (en)	2014-06-23	2017-04-26	Novartis AG	Hsa-gdf-15 fusion polypeptide and use thereof
RU2017101436A (ru)	2014-06-24	2018-07-24	Ново Нордиск А/С	Mic-1 слитные белки и их применение
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
SG11201700378PA (en)	2014-07-30	2017-02-27	Ngm Biopharmaceuticals Inc	Compositions and methods of use for treating metabolic disorders
US9988443B2 (en)	2014-08-07	2018-06-05	Novartis Ag	Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
DK3177642T3 (da)	2014-08-07	2022-02-21	Novartis Ag	Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016029131A1 (en) *	2014-08-22	2016-02-25	National Cheng Kung University	Disintegrin variants and pharmaceutical uses thereof
CA2961382C (en)	2014-09-17	2024-02-13	Bayer Cropscience Lp	Compositions comprising recombinant bacillus cells and another biological control agent
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AP2017009826A0 (en)	2014-09-26	2017-03-31	Bayer Pharma AG	Stabilized adrenomedullin derivatives and use thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201700181A1 (ru)	2014-10-14	2017-09-29	Галозим, Инк.	Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
DK3212226T3 (da)	2014-10-31	2020-06-15	Ngm Biopharmaceuticals Inc	Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
AR103243A1 (es)	2014-12-23	2017-04-26	Merz Pharma Gmbh & Co Kgaa	Recipiente precargado con toxina botulínica
WO2016161010A2 (en) *	2015-03-30	2016-10-06	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to fc gamma receptors
JP2016204292A (ja) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
US20180086809A1 (en) *	2015-04-29	2018-03-29	Mediolanum Farmaceutici S.P.A.	A soluble chimeric interleukin-10 receptor and therapeutic use thereof
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (en) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Methods of treatment for conditions mediated by substance p
CA2982237A1 (en)	2015-06-05	2016-12-08	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2016201202A1 (en) *	2015-06-11	2016-12-15	Attwill Medical Solutions Inc.	Medical devices, systems, and methods utilizing antithrombin-heparin compositions
JOP20200312A1 (ar)	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
EP3328415B1 (en) *	2015-07-30	2020-11-25	Endor Technologies, S.L.	Colony stimulating factor for use in pancreatic or colon cancer treatment
WO2017021893A1 (en)	2015-08-03	2017-02-09	Novartis Ag	Methods of treating fgf21-associated disorders
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017024198A1 (en) *	2015-08-06	2017-02-09	The Trustees Of The University Of Pennsylvania	Glp-1 and use thereof in compositions for treating metabolic diseases
US10633428B2 (en)	2015-08-20	2020-04-28	Albumedix Ltd	Albumin variants and conjugates
KR102360744B1 (ko)	2015-09-08	2022-02-08	제이씨알 파마 가부시키가이샤	신규 인간 혈청 알부민 변이체
MY186352A (en)	2015-09-09	2021-07-15	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MX2018003038A (es)	2015-09-09	2018-04-11	Novartis Ag	Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
JP7299021B2 (ja)	2015-09-11	2023-06-27	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	生体関連の直交性サイトカイン／受容体ペア
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
US10597449B2 (en)	2015-12-04	2020-03-24	Boehringer Ingelheim International Gmbh	Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
CN108602893A (zh)	2015-12-11	2018-09-28	戴埃克斯有限公司	血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
AU2016370813A1 (en)	2015-12-18	2018-06-28	Novartis Ag	Antibodies targeting CD32b and methods of use thereof
WO2017109706A1 (en)	2015-12-22	2017-06-29	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
MA43859A (fr)	2016-01-11	2018-11-21	Novartis Ag	Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
ES2847155T3 (es)	2016-01-21	2021-08-02	Novartis Ag	Moléculas multiespecíficas que fijan como objetivo CLL-1
HRP20221089T1 (hr)	2016-02-01	2022-11-25	Bioverativ Therapeutics Inc.	Optimizirani geni faktora viii
EP3431508A4 (en)	2016-03-14	2019-08-14	JCR Pharmaceuticals Co., Ltd.	SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN
US10745487B2 (en)	2016-03-22	2020-08-18	Bionomics Limited	Method of treating cancer by administering an anti-LGR5 monoclonal antibody
SG11201807279QA (en)	2016-03-31	2018-09-27	Ngm Biopharmaceuticals Inc	Binding proteins and methods of use thereof
AU2017247004B2 (en)	2016-04-06	2022-07-07	Csl Limited	Method of treating atherosclerosis
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
EP3458478B1 (en)	2016-05-18	2021-01-06	Boehringer Ingelheim International GmbH	Anti pd-1 and anti-lag3 antibodies for cancer treatment
TW201741333A (zh)	2016-05-24	2017-12-01	諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
KR102492057B1 (ko)	2016-06-15	2023-01-26	노파르티스 아게	골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
WO2018007601A1 (en) *	2016-07-08	2018-01-11	Csl Behring Recombinant Facility Ag	Subcutaneous administration of long-acting factor ix in humans
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
WO2018024873A1 (en)	2016-08-05	2018-02-08	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja)	2016-08-23	2019-11-28	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
WO2018082758A1 (en)	2016-11-04	2018-05-11	Aarhus Universitet	Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
US11324804B2 (en) *	2016-11-18	2022-05-10	Sepsia Therapeutics, S.L.	Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
IL308416B2 (en)	2016-12-02	2025-08-01	Bioverativ Therapeutics Inc	Methods of treating hemophilic arthropathy using chimeric clotting factors
US12257288B2 (en)	2016-12-02	2025-03-25	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3562840A1 (en)	2016-12-16	2019-11-06	Biogen MA Inc.	Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2018119354A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Gene editing of pcsk9
CN110325550B (zh)	2016-12-23	2024-03-08	诺华股份有限公司	因子xi抗体和使用方法
JP7110199B2 (ja)	2016-12-23	2022-08-01	ノバルティスアーゲー	抗第ＸＩ／ＸＩａ因子抗体による処置法
WO2018132768A1 (en)	2017-01-13	2018-07-19	Sanna Pietro P	Methods and compositions for treating hpa hyperactivity
CR20190389A (es)	2017-01-31	2019-11-26	Bioverativ Therapeutics Inc	Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
ES3035810T3 (en)	2017-02-08	2025-09-09	Novartis Ag	Fgf21 mimetic antibodies and uses thereof
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018193033A1 (en)	2017-04-20	2018-10-25	Novo Nordisk A/S	Methods of purification of albumin fusion proteins
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
MX2019014023A (es)	2017-05-24	2020-02-17	Novartis Ag	Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
MX2019014331A (es)	2017-05-31	2020-01-27	Boehringer Ingelheim Int	Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
US11253579B2 (en)	2017-06-16	2022-02-22	The University Of Chicago	Compositions and methods for inducing immune tolerance
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
SG10202111032PA (en)	2017-06-29	2021-11-29	CSL Behring Lengnau AG	21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
EP3661562B1 (en)	2017-08-04	2024-10-02	Amgen Inc.	Method of conjugation of cys-mabs
TWI904068B (zh)	2017-08-09	2025-11-11	美商生物化學醫療公司	核酸分子及其用途
WO2019036605A2 (en)	2017-08-17	2019-02-21	Massachusetts Institute Of Technology	MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US12059456B2 (en)	2017-09-15	2024-08-13	Cedars-Sinai Medical Center	Methods of using C1 esterase inhibitor for improving early onset and long-term function of kidney transplants from grafts associated with delayed graft function
WO2019075519A1 (en) *	2017-10-18	2019-04-25	Csl Limited	HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
US20210040205A1 (en)	2017-10-25	2021-02-11	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
US11505619B2 (en)	2017-12-15	2022-11-22	Csl Limited	Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
SG11202004158QA (en)	2017-12-28	2020-06-29	Nanjing Legend Biotech Co Ltd	Single-domain antibodies and variants thereof against tigit
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
CN111699200B (zh)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	针对pd-1的单域抗体和其变体
WO2019152692A1 (en)	2018-02-01	2019-08-08	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing factor viii
RS64455B1 (sr) *	2018-03-13	2023-09-29	Sepsia Therapeutics S L	Peptidi koji vezuju bakterije, za lečenje infektivnih bolesti i povezanih inflamatornih procesa
FI3765525T3 (fi)	2018-03-13	2023-10-16	Zymeworks Bc Inc	Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
TWI853807B (zh)	2018-03-28	2024-09-01	美商必治妥美雅史谷比公司	介白素-2/介白素-2受體阿法融合蛋白及其使用方法
EP3774917B1 (en)	2018-03-30	2025-10-29	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against lag-3 and uses thereof
KR102119197B1 (ko) *	2018-04-23	2020-06-05	주식회사 엘베이스	세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
SG11202011078VA (en)	2018-05-09	2020-12-30	Univ Chicago	Compositions and methods concerning immune tolerance
CN113840832A (zh)	2018-05-14	2021-12-24	狼人治疗公司	可活化白介素-2多肽及其使用方法
WO2019222294A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US11492409B2 (en)	2018-06-01	2022-11-08	Novartis Ag	Binding molecules against BCMA and uses thereof
JP2021529516A (ja)	2018-06-18	2021-11-04	アンウィタバイオサイエンシス，インク．	サイトカイン融合タンパク質及びその使用
CA3104686A1 (en)	2018-07-03	2020-01-09	Bristol-Myers Squibb Company	Fgf-21 formulations
CA3108799A1 (en)	2018-08-09	2020-02-13	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
HRP20250234T1 (hr)	2018-08-31	2025-04-11	Regeneron Pharmaceuticals, Inc.	Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela
WO2020058759A1 (en) *	2018-09-17	2020-03-26	Kyoto University	Administration of an anti-c5 agent for treatment of hepatic injury or failure
EP3856764A4 (en)	2018-09-27	2022-11-02	Xilio Development, Inc.	MASKED CYTOKINE POLYPEPTIDES
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
KR20210111245A (ko) *	2018-10-29	2021-09-10	스핀 테라퓨틱스, 엘엘씨	알파-1-항트립신 장애들을 위한 조성물들 및 방법들
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
CN113396158A (zh)	2018-11-26	2021-09-14	诺华股份有限公司	Lpl-gpihbp1融合多肽
AU2019393880A1 (en)	2018-12-06	2021-07-15	Bioverativ Therapeutics Inc.	Use of lentiviral vectors expressing factor IX
WO2020198075A2 (en)	2019-03-22	2020-10-01	Reflexion Pharmaceuticals, Inc.	Multivalent d-peptidic compounds for target proteins
KR20220044612A (ko)	2019-03-22	2022-04-08	리플렉시온 파마슈티컬스, 인크.	Vegf에 대한 d-펩티드성 화합물
EP3947442A2 (en)	2019-03-28	2022-02-09	Danisco US Inc.	Engineered antibodies
MX2021012250A (es)	2019-04-11	2022-01-18	Angion Biomedica Corp	Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
SG11202112541RA (en)	2019-05-14	2021-12-30	Werewolf Therapeutics Inc	Separation moieties and methods and use thereof
EP3972993A1 (en)	2019-05-21	2022-03-30	Novartis AG	Variant cd58 domains and uses thereof
KR20250156861A (ko)	2019-05-21	2025-11-03	노파르티스 아게	Cd19 결합 분자 및 이의 용도
US11827671B2 (en)	2019-05-24	2023-11-28	Sanofi	Methods for treating systemic sclerosis
JP2022537369A (ja)	2019-06-18	2022-08-25	バイエルアクチェンゲゼルシャフト	長期安定化のためのアドレノメデュリン－類似体およびその使用
JP7671739B2 (ja)	2019-09-06	2025-05-02	ノバルティスアーゲー	治療用融合タンパク質
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
WO2021067389A1 (en)	2019-09-30	2021-04-08	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
JP2021066730A (ja) *	2019-10-17	2021-04-30	Ｊｃｒファーマ株式会社	血清アルブミンと成長ホルモンの融合蛋白質の製造方法
JP7604174B2 (ja)	2019-10-30	2024-12-23	Ｊｃｒファーマ株式会社	血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物
JP2023503258A (ja)	2019-11-14	2023-01-27	ウェアウルフセラピューティクス，インコーポレイテッド	活性化可能サイトカインポリペプチド及びその使用方法
EP4069200A1 (en)	2019-12-04	2022-10-12	Albumedix Ltd	Methods and compositions produced thereby
US11648296B2 (en)	2019-12-13	2023-05-16	Synthekine, Inc.	IL-2 orthologs and methods of use
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
US12358963B2 (en)	2019-12-24	2025-07-15	Juvena Therapeutics, Inc.	Regenerative polypeptides and uses thereof
JP2023510854A (ja)	2020-01-13	2023-03-15	武田薬品工業株式会社	小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
WO2021202473A2 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Engineered antibodies
JP7457833B2 (ja)	2020-04-09	2024-03-28	ヴァーヴ・セラピューティクス，インコーポレーテッド	Ａｎｇｐｔｌ３の塩基編集および疾患の処置のためにこれを使用する方法
KR20230012559A (ko)	2020-05-19	2023-01-26	베링거 인겔하임 인터내셔날 게엠베하	암 치료를 위한 결합 분자
JP2023529497A (ja)	2020-06-14	2023-07-10	バーテックスファーマシューティカルズインコーポレイテッド	補体因子ｉ関連組成物および方法
EP4171657A1 (en)	2020-06-24	2023-05-03	Bioverativ Therapeutics Inc.	Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
AR123862A1 (es)	2020-10-21	2023-01-18	Boehringer Ingelheim Int	Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
CN116406374A (zh) *	2020-10-30	2023-07-07	深圳普罗吉医药科技有限公司	人血清白蛋白在治疗疾病中的应用
EP4240491A1 (en)	2020-11-06	2023-09-13	Novartis AG	Cd19 binding molecules and uses thereof
JP2023553323A (ja)	2020-11-25	2023-12-21	エクシリオデベロップメント，インコーポレイテッド	腫瘍特異的に切断可能なリンカー
CN114478800B (zh) *	2021-02-05	2022-10-11	华南理工大学	基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
WO2022178255A2 (en)	2021-02-19	2022-08-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies that neutralize sars-cov-2
EP4355778A1 (en)	2021-06-17	2024-04-24	Boehringer Ingelheim International GmbH	Novel tri-specific binding molecules
IL309562A (en) *	2021-06-21	2024-02-01	Juvena Therapeutics Inc	Regenerative polypeptides and their uses
CN114133458B (zh) *	2021-12-08	2023-11-14	福州大学	一种在人血清白蛋白内部融合多肽的方法
CA3255838A1 (en)	2022-04-26	2023-11-02	Novartis Ag	MULTISPECIFIC ANTIBODIES TARGETTING IL-13 AND IL-18
JP2025523031A (ja)	2022-07-15	2025-07-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	がんの処置のための結合性分子
EP4554619A1 (en)	2022-07-15	2025-05-21	Danisco US Inc.	Methods for producing monoclonal antibodies
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
TW202440624A (zh) *	2022-12-20	2024-10-16	澳大利亞商杰特創新股份有限公司	FcRn拮抗劑及其用途
EP4389762A1 (en)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations and uses thereof
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025072888A2 (en)	2023-09-28	2025-04-03	Novavax, Inc.	Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (de) *	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
NO164037C (no)	1980-01-08	1990-08-22	Biogen Inc	Fremgangsmaate ved fremstilling av et polypeptid av interferon alfa (ifnalfa)-type.
AU564690B2 (en)	1980-04-03	1987-08-20	Biogen Idec Ma Inc.	Process for producing human fibroblast interferon-like polypeptides using recombinant dna
DE3023787A1 (de)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
IT1139487B (it)	1980-09-25	1986-09-24	Genentech Inc	Produzione microbica di interferone di fibroblasti umani
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
ATE12348T1 (de)	1980-11-10	1985-04-15	Gersonde Klaus Prof Dr	Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
WO1982002715A1 (fr)	1981-02-04	1982-08-19	Sugano Haruo	Gene d'interferon (beta)humain
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en) *	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
CA1204682A (en)	1981-06-19	1986-05-20	Saran A. Narang	Adaptors, and synthesis and cloning of proinsulin genes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (en)	1981-11-12	1984-08-08	The Upjohn Company	Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58107298A (ja)	1981-12-21	1983-06-25	Yoshitsuka Seiki:Kk	粉末成形プレスにおけるシエ−カ−カムの位相調整装置
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
WO1983002461A1 (en)	1982-01-19	1983-07-21	Cetus Corp	Multiclass hybrid interferons
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
US4738927A (en)	1982-03-31	1988-04-19	Ajinomoto Co. Inc.	Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
CA1341562C (en)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US5824330A (en)	1982-04-20	1998-10-20	Sloan-Kettering Institute For Cancer Research	Highly purified interleukin-2 and method
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4490289A (en)	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
JPS5945835U (ja)	1982-09-16	1984-03-27	株式会社東芝	回路しや断器の消弧装置
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
FI82266C (fi)	1982-10-19	1991-02-11	Cetus Corp	Foerfarande foer framstaellning av il-2 -mutein.
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
EP0116201B1 (en)	1983-01-12	1992-04-22	Chiron Corporation	Secretory expression in eukaryotes
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
DK172738B1 (da)	1983-04-07	1999-06-21	Chiron Corp	Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
WO1984004330A1 (en)	1983-04-22	1984-11-08	Amgen	Secretion of exogenous polypeptides from yeast
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Slow release injectable insulin composition
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (ja)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	雑種制御領域
ATE159858T1 (de)	1983-09-26	1997-11-15	Ehrenfeld Udo	Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
JPS60115528A (ja)	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (ja)	1983-12-26	1985-07-20	Suntory Ltd	ペプチド及びこれを有効成分とする利尿剤
IT1185503B (it)	1984-01-11	1987-11-12	Univ New York	Cloni di odna di eritropietina umana
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
CA1213537A (en)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Polypeptide expression method
FR2564106B1 (fr) *	1984-05-09	1988-04-22	Transgene Sa	Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
DK58285D0 (da)	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
EP0172619A1 (en)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Novel transformant and use thereof
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (ja)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en) *	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en) *	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
DK129385A (da)	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
FR2579224B1 (fr) *	1985-03-25	1987-05-22	Genetica	Procede de preparation microbiologique de la serum-albumine humaine
US4751180A (en) *	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
EP0196056B1 (en)	1985-03-28	1991-05-22	Chiron Corporation	Improved expression using fused genes providing for protein product
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
EP0206733A1 (en)	1985-06-17	1986-12-30	Genex Corporation	Cloned human serum albumin gene
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPH0618778B2 (ja)	1985-10-04	1994-03-16	中外製薬株式会社	白血球減少症治療剤
JPS6296086A (ja)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	複合プラスミド
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
WO1987002671A1 (en)	1985-11-01	1987-05-07	International Genetic Engineering, Inc.	Modular assembly of antibody genes, antibodies prepared thereby and use
CA1295563C (en)	1985-11-01	1992-02-11	Robert T. Garvin	Production of active proteins containing cystine residues
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
CA1295566C (en)	1987-07-21	1992-02-11	Robert T. Garvin	Characterization and structure of genes for protease a and protease b from streptomyces griseus
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
JPH0780930B2 (ja)	1985-12-26	1995-08-30	三井石油化学工業株式会社	α−オレフインの重合方法
JPH0645551B2 (ja)	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
ATE65403T1 (de)	1986-01-22	1991-08-15	Chugai Pharmaceutical Co Ltd	Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DE3777845D1 (de)	1986-01-22	1992-05-07	Chugai Pharmaceutical Co Ltd	Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (fr) *	1986-02-21	1989-10-20	Genetica	Procede de preparation de la serum albumine humaine mature
EP0237019A3 (en)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interferon conjugate and production thereof using recombinant gene
IT1203758B (it)	1986-03-27	1989-02-23	Univ Roma	Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
DK179286D0 (da)	1986-04-18	1986-04-18	Nordisk Gentofte	Insulinpraeparat
US4765980A (en) *	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en)	1986-05-29	1999-11-16	The Austin Research Institute	FC receptor for immunoglobulin
IT1204400B (it) *	1986-06-20	1989-03-01	Sclavo Spa	Composizioni farmaceutiche contenente una calcitonina
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (it)	1986-07-11	1988-11-16	Sclavo Spa	Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en)	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) *	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
FI885224A7 (fi)	1987-03-23	1988-11-11	Amgen Inc	Puhdistettu verihiutaleista peräisin oleva kasvutekijä ja menetelmiä s en puhdistamiseksi
IE63424B1 (en) *	1987-04-09	1995-04-19	Delta Biotechnology Ltd	Yeast vector
EP0682110A1 (en)	1987-04-22	1995-11-15	Chiron Corporation	Recombinant DNA encoding PDGF A-chain polypeptides
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
ATE97446T1 (de)	1987-07-28	1993-12-15	Gist Brocades Nv	Kluyveromyces als wirtsstamm.
JPH0622784Y2 (ja)	1987-08-04	1994-06-15	東洋シヤッター株式会社	オ−バ−ドア用可動中柱の高さ調整装置
JP2627899B2 (ja)	1987-08-19	1997-07-09	株式会社ビタミン研究所	遺伝子封入リポソームの製法
SE459586B (sv)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
PT88641B (pt)	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
JPH0811074B2 (ja)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
GB8725529D0 (en) *	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
JP2791418B2 (ja)	1987-12-02	1998-08-27	株式会社ミドリ十字	異種蛋白質の製造方法、組換えｄｎａ、形質転換体
US5282856A (en)	1987-12-22	1994-02-01	Ledergerber Walter J	Implantable prosthetic device
ZA89430B (en)	1988-01-22	1989-10-25	Gen Hospital Corp	Cloned genes encoding ig-cd4 fusion proteins and the use thereof
JPH01240191A (ja) *	1988-02-16	1989-09-25	Green Cross Corp:The	酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
JPH01215289A (ja)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89989A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
ATE101620T1 (de)	1988-06-23	1994-03-15	Hoechst Ag	Mini-proinsulin, seine herstellung und verwendung.
ZA894792B (en)	1988-06-24	1991-04-24	Dow Chemical Co	Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
AU634167B2 (en)	1988-06-24	1993-02-18	Dow Chemical Company, The	Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
ATE135045T1 (de) *	1988-07-23	1996-03-15	Delta Biotechnology Ltd	Sekretorische leader-sequenzen
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2635115B1 (fr)	1988-08-05	1992-04-03	Rhone Poulenc Sante	Procede de preparation de la serum albumine humaine a partir d'une levure
FR2649991B2 (fr)	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
JPH04501204A (ja)	1988-08-11	1992-03-05	サイオス　ノバ　インコーポレイテッド	異種タンパク発現を安定させる方法およびそれに使用するベクター
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DE768377T1 (de)	1988-09-02	1998-01-02	Dyax Corp	Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (ja)	1988-10-06	1990-09-10	Tonen Corp	ヒト血清アルブミン断片
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
JPH02117384A (ja)	1988-10-26	1990-05-01	Tonen Corp	酵母宿主によるヒト血清アルブミンａの製造
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
CA2345497A1 (en)	1988-10-28	1990-04-28	Genentech, Inc.	Growth hormone variants and method for forming growth hormone variants
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
CA2006596C (en)	1988-12-22	2000-09-05	Rika Ishikawa	Chemically-modified g-csf
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DK105489D0 (da) *	1989-03-03	1989-03-03	Novo Nordisk As	Polypeptid
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en)	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
JPH04504246A (ja)	1989-03-20	1992-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン刺激ホルモン
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
EP1026253B2 (en)	1989-03-21	2012-12-19	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0392300T3 (da) *	1989-04-11	1992-09-28	Boehringer Ingelheim Int	Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
EP0395918A3 (en)	1989-04-13	1991-10-23	Vascular Laboratory, Inc.	Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
ATE92107T1 (de)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
ATE155813T1 (de)	1989-05-19	1997-08-15	Genentech Inc	Her2 extrazellulare domäne
DE69024261T2 (de)	1989-05-24	1996-07-18	Merck & Co Inc	Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
US5330971A (en) *	1989-06-09	1994-07-19	Gropep Pty. Ltd.	Growth hormone fusion proteins, methods of production, and methods of treatment
JPH0327320A (ja)	1989-06-26	1991-02-05	Ajinomoto Co Inc	ヒトｂ細胞分化因子医薬組成物
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (de) *	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CU22222A1 (es)	1989-08-03	1995-01-31	Cigb	Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
FR2650598B1 (fr) *	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
EP0489116B1 (en)	1989-08-22	1994-04-06	Immunex Corporation	Fusion proteins comprising gm-csf and il-3
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en)	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
WO1991005052A1 (fr)	1989-09-28	1991-04-18	Leningradsky Gosudarstvenny Universitet	Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae
ATE168416T1 (de)	1989-10-05	1998-08-15	Optein Inc	Zellfreie synthese und isolierung von genen und polypeptiden
FR2653020B1 (fr)	1989-10-17	1993-03-26	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
WO1991006309A1 (en)	1989-11-03	1991-05-16	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
DK608589D0 (da)	1989-12-01	1989-12-01	Holm Arne	Kemisk fremgangsmaade
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5116944A (en) *	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
JPH03201987A (ja)	1989-12-29	1991-09-03	Tonen Corp	ヒト血清アルブミン断片
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
DK0439442T3 (da) *	1990-01-25	1996-07-08	Univ Washington	Faktor X-LACI-hybridprotein
JPH04211375A (ja)	1990-02-05	1992-08-03	Ajinomoto Co Inc	合成遺伝子及びそれを用いたヒト血清アルブミンの製造法
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (fr) *	1990-04-17	1994-01-21	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
WO1991018088A1 (en)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en)	1990-06-11	1990-08-01	Mars Uk Ltd	Compounds
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
CA2084514A1 (en)	1990-07-10	1992-01-11	Guenther Adolf	O-glycosylated ifn-alpha
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (it)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
CA2093022C (en)	1990-10-05	2005-02-22	Michael W. Fanger	Targeted immunostimulation with bispecific reagents
JPH07108232B2 (ja)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	ペプチド又は蛋白質の製造方法
JPH0638771Y2 (ja)	1990-10-26	1994-10-12	株式会社カンセイ	エアバック制御装置
EP0557300B1 (en)	1990-10-29	1997-11-19	Chiron Corporation	Bispecific antibodies, method of production, and uses thereof
FR2668368B1 (fr)	1990-10-30	1995-03-10	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
JPH0638771A (ja)	1990-10-31	1994-02-15	Tonen Corp	ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
US5830452A (en)	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
JP3366947B2 (ja)	1990-11-29	2003-01-14	アンスティテュナシオナルドラルシェルシュアグロノミクーイ．エン．エル．アー．	タイプ１インターフェロン由来の新規変異体、それらの製造方法及びそれらの適用
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en) *	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en)	1991-03-12	1992-09-13	Yasutaka Igari	Composition for sustained-release of erythropoietin
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
DE69229454T2 (de)	1991-03-28	2000-01-05	Merck & Co., Inc.	Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
ATE269401T1 (de)	1991-04-10	2004-07-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
WO1992019973A1 (en)	1991-04-26	1992-11-12	Surface Active Limited	Novel antibodies, and methods for their use
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
FR2676070B1 (fr)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisation.
US5646012A (en)	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
EP0590067A1 (en)	1991-06-14	1994-04-06	Xoma Corporation	Microbially-produced antibody fragments and their conjugates
FR2677996B1 (fr)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	Vecteurs de clonage et/ou d'expression preparation et utilisation.
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
WO1993000109A1 (en)	1991-06-28	1993-01-07	Genentech, Inc.	Method of stimulating immune response using growth hormone
US5223408A (en)	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (ja)	1991-07-29	1993-11-09	Tonen Corp	改良された酵母発現系
AU669484B2 (en)	1991-07-31	1996-06-13	Peri Development Applications (1985) Ltd	Transgenic protein production
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
PT101031B (pt) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
DE69226197T2 (de)	1991-11-08	1999-02-11	Somatogen, Inc., Boulder	Hämoglobine als arzneimittelabgabesystem
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU671093B2 (en)	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
GB9200417D0 (en)	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (fr) *	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	Serum-albumine humaine, preparation et utilisation.
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) *	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
ATE503496T1 (de)	1992-02-06	2011-04-15	Novartis Vaccines & Diagnostic	Biosynthetisches bindeprotein für tumormarker
ES2193143T3 (es)	1992-03-05	2003-11-01	Univ Texas	Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
USRE37302E1 (en)	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
ATE182651T1 (de)	1992-06-09	1999-08-15	Hoppe Ag	Riegel und türschloss
CZ315594A3 (en)	1992-06-15	1995-07-12	Pfizer	Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
US5686268A (en) *	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (ja)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	ヒト血清アルブミンの製造方法
FR2694294B1 (fr) *	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisateur.
DE69329651T3 (de)	1992-07-31	2008-10-30	Genentech, Inc., South San Francisco	Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4226971C2 (de) *	1992-08-14	1997-01-16	Widmar Prof Dr Tanner	Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en)	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en) *	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (fr)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
US5441734A (en) *	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en) *	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1994024160A2 (en)	1993-04-21	1994-10-27	Brigham And Women's Hospital	Erythropoietin muteins with enhanced activity
GB9308581D0 (en)	1993-04-26	1993-06-09	Univ Manitoba	A method for induction of antigen-specific suppression of immune-response
ES2169074T3 (es) *	1993-05-21	2002-07-01	Novo Nordisk Healthcare Ag	Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.
WO1994029469A2 (en)	1993-06-07	1994-12-22	Vical Incorporated	Plasmids suitable for gene therapy
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (da) *	1993-07-08	1993-07-08	Novo Nordisk As	Peptid
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
AU693459B2 (en)	1993-08-09	1998-07-02	Edward Baral	A method for sensitization of cancer cells for killer cell mediated lysis
ZA946122B (en)	1993-08-17	1995-03-20	Amgen Inc	Erythropoietin analogs
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
WO1995005848A1 (en)	1993-08-24	1995-03-02	Novo Nordisk A/S	Protracted glp-1
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
AU696293B2 (en)	1993-12-08	1998-09-03	Genzyme Corporation	Process for generating specific antibodies
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en)	1993-12-09	1995-06-21	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
AU1272295A (en)	1993-12-17	1995-07-03	Novo Nordisk A/S	Proinsulin-like compounds
DK144093D0 (ru)	1993-12-23	1993-12-23	Novo Nordisk As
PT1231268E (pt)	1994-01-31	2005-11-30	Univ Boston	Bancos de anticorpos policlonais
US5550214A (en)	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5652352A (en)	1994-03-31	1997-07-29	Amgen Inc.	Afamin: a human serum albumin-like gene
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (fr)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en)	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
JPH10506004A (ja)	1994-07-27	1998-06-16	ザカウンシルオブザクィーンズランドインスティテュートオブメディカルリサーチ	ポリエピトープワクチン
JPH0853500A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	融合タンパク質および該タンパク質をコードする遺伝子
JPH0851982A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	ヒト血清アルブミンをコードする改変された遺伝子
JPH0859509A (ja)	1994-08-16	1996-03-05	Teijin Ltd	サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ES2285701T3 (es)	1994-11-07	2007-11-16	Human Genome Sciences, Inc.	Factor-gamma de necrosis tumoral.
FR2726576B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
FR2726471B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
AT403167B (de)	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
WO1996017941A2 (en)	1994-12-07	1996-06-13	Bionebraska, Inc.	Production of c-terminal amidated peptides from recombinant protein constructs
CA2206848A1 (en)	1994-12-07	1996-06-13	Bionebraska, Inc.	Production of peptides using recombinant fusion protein constructs
EP0793504B1 (en) *	1994-12-12	2005-06-08	Beth Israel Deaconess Medical Center, Inc.	Chimeric cytokines and uses thereof
DE69529998D1 (de)	1994-12-23	2003-04-24	Novo Nordisk As	Glp-1 zusammensetzungen mit verlängerter wirkdauer
US20010006943A1 (en)	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
US5583415A (en)	1994-12-27	1996-12-10	Motorola, Inc.	Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
JP2758154B2 (ja)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
WO1996034095A1 (en)	1995-04-27	1996-10-31	Human Genome Sciences, Inc.	Human tumor necrosis factor receptors
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
AU5724996A (en)	1995-05-05	1996-11-21	Eli Lilly And Company	Single chain insulin with high bioactivity
CA2220123A1 (en)	1995-05-05	1996-11-07	Human Genome Sciences, Inc.	Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6387365B1 (en)	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US5741815A (en)	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en)	1995-07-28	1998-11-24	Mogam Biotechnology Research Institute	Method for manufacture of proinsulin with high export yield
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH0995455A (ja)	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	腎機能改善剤
US5766620A (en) *	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
JP2000507917A (ja)	1995-11-02	2000-06-27	シェーリングコーポレイション	持続的低用量サイトカイン注入治療
US6048964A (en) *	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en)	1995-12-28	2000-06-27	Dendreon Corporation	Immunostimulatory method
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
AU718254B2 (en)	1996-01-19	2000-04-13	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
US6087129A (en)	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
US6110707A (en)	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
DE19639601A1 (de)	1996-02-28	1997-09-04	Bayer Ag	Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP4064460B2 (ja)	1996-03-01	2008-03-19	ノボノルディスクアクティーゼルスカブ	食欲抑制性ペプチドを含む医薬組成物の用途
JP3794748B2 (ja) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	メタノール代謝系を有する微生物の培養法
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
AU702567B2 (en)	1996-03-13	1999-02-25	Novozymes Biopharma Dk A/S	Fermentation control
WO1997033899A1 (en)	1996-03-14	1997-09-18	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997033998A1 (en)	1996-03-14	1997-09-18	The Immune Response Corporation	Targeted delivery of genes encoding interferon
CA2248136A1 (en)	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Human endometrial specific steroid-binding factor i, ii and iii
EP0904278A4 (en)	1996-03-22	1999-09-15	Human Genome Sciences Inc	MOLECULE II INDUCER OF APOPTOSIS
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
AU2667197A (en)	1996-04-16	1997-11-07	University Of Miami	Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
US6497878B1 (en) *	1996-04-23	2002-12-24	Chugai Seiyaku Kabushiki Kaisha	Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
EP0914116B1 (en) *	1996-05-22	2000-10-11	Protarga Inc.	Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
ATE277172T1 (de) *	1996-06-11	2004-10-15	Roche Diagnostics Gmbh	Rekombinante blutgerinnungsproteasen
US6110891A (en)	1996-06-21	2000-08-29	Alizyme Therapeutics Ltd.	Lectin compositions and uses thereof
GB2318352A (en)	1996-06-25	1998-04-22	Dejan Markovic	Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en)	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
US5932547A (en)	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
DE69733204T3 (de)	1996-07-15	2012-03-08	Chugai Seiyaku K.K.	Neuartige vegf-ähnliche faktoren
AR008077A1 (es)	1996-07-26	1999-12-09	Talarico Salinas Laura Beatriz	Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
US5959075A (en)	1996-08-02	1999-09-28	Zymogenetics, Inc.	Testis-specific insulin homolog polypeptides
US6190533B1 (en)	1996-08-15	2001-02-20	Exxon Chemical Patents Inc.	Integrated hydrotreating steam cracking process for the production of olefins
AU4055697A (en)	1996-08-16	1998-03-06	Schering Corporation	Mammalian cell surface antigens; related reagents
ES2316153T3 (es)	1996-08-16	2009-04-01	Human Genome Sciences, Inc.	Endoquina alfa humana.
CA2263890C (en)	1996-08-23	2013-05-14	Ludwig Institute For Cancer Research	Recombinant vascular endothelial cell growth factor d (vegf-d)
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5922761A (en)	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
AU4199597A (en)	1996-09-09	1998-04-02	Novo Nordisk A/S	A cdna and peptide with relation to cancer and weight loss
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
EP0961832A4 (en) *	1996-09-18	2003-02-26	Human Genome Sciences Inc	HUMAN TUMOR NECROSIS FACTOR-TYPE RECEPTOR GENES
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
CN100415772C (zh)	1996-10-18	2008-09-03	基因技术股份有限公司	抗ErbB2抗体
AU4988697A (en)	1996-10-24	1998-05-15	Vion Pharmaceuticals, Inc.	Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
CA2266439C (en)	1996-10-25	2009-06-16	Human Genome Sciences, Inc.	Neutrokine .alpha.
JPH10134761A (ja)	1996-10-30	1998-05-22	Ebara Corp	イオン注入装置及びイオン注入方法
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
UA65549C2 (ru)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
EP1306092A3 (en)	1996-11-05	2003-05-07	Eli Lilly & Company	Use of GLP-1 and analogs administered peripherally, in regulation of obesity
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
DE69732572T2 (de)	1996-11-12	2005-12-29	Novo Nordisk A/S	Verwendung von glp-1 peptiden
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6130248A (en)	1996-12-30	2000-10-10	Bar-Ilan University	Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
WO1998030693A2 (en)	1997-01-14	1998-07-16	Human Genome Sciences, Inc.	Tumor necrosis factor receptor 5
EP0954589A1 (en) *	1997-01-24	1999-11-10	Novo Nordisk A/S	Synthetic leader peptide sequences
JP4450870B2 (ja)	1997-01-28	2010-04-14	ヒューマンジノームサイエンシーズ，インコーポレイテッド	死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
DE69800640T2 (de)	1997-01-29	2001-07-05	Polymasc Pharmaceuticals Plc, London	Pegylationsverfahren
EP0981635A1 (en)	1997-02-13	2000-03-01	Applied Phytologics, Inc.	Production of mature proteins in plants
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en) *	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
US5939455A (en)	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6124495A (en)	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US6110955A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6110970A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US5846774A (en)	1997-03-21	1998-12-08	Bionebraska, Inc.	Chlorella virus promoters
CA2283834A1 (en)	1997-03-31	1998-10-08	James Arthur Hoffmann	Glucagon-like peptide-1 analogs
PT970126E (pt)	1997-04-14	2001-10-30	Micromet Ag	Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
TW577759B (en)	1997-04-18	2004-03-01	Ipsen Pharma Biotech	Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU7273598A (en)	1997-05-05	1998-11-27	Regents Of The University Of California, The	Naphthols useful in antiviral methods
JP2002511070A (ja)	1997-05-30	2002-04-09	ヒューマンジノームサイエンシーズ，インコーポレイテッド	ヒト腫瘍壊死因子受容体ｔｒ１０
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
JP2002503963A (ja)	1997-06-11	2002-02-05	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	ヒト腫瘍壊死因子受容体ｔｒ９
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
ATE255634T1 (de)	1997-09-01	2003-12-15	Aventis Pharma Gmbh	Rekombinantes humanes erythropoietin mit vorteilhaftem glykosylierungsmuster
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DE69810822T2 (de)	1997-09-21	2003-11-20	Schering Corp., Kenilworth	Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection
ES2223017T5 (es)	1997-09-23	2010-10-15	Rentschler Biotechnologie Gmbh	Formulaciones liquidas de un interferon beta.
US6117949A (en)	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en)	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP2001519179A (ja) *	1997-10-09	2001-10-23	ヒューマンジノームサイエンシーズ，インコーポレイテッド	５３個のヒト分泌タンパク質
WO1999023105A1 (en)	1997-11-03	1999-05-14	Human Genome Sciences, Inc.	Vegi, an inhibitor of angiogenesis and tumor growth
CN1280309C (zh)	1997-12-03	2006-10-18	罗切诊断学有限公司	具有高比活的促红细胞生成素
CA2312190A1 (en)	1997-12-05	1999-06-17	Eli Lilly And Company	Glp-1 formulations
DK1037927T3 (da)	1997-12-08	2004-09-06	Emd Lexigen Res Ct Corp	Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
DE69822505T2 (de) *	1997-12-08	2005-01-20	Bristol-Myers Squibb Co.	Neue metformin-salze und verfahren
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR100253916B1 (ko)	1997-12-29	2000-05-01	김충환	사람 인슐린 전구체의 제조방법
US5951996A (en)	1998-02-04	1999-09-14	Czeizler Zaharia; Veronica L.	Treatment of chronic diffuse GI bleeding with erythropoietin
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
CA2320371C (en)	1998-02-13	2012-01-17	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and glp-1
DE69942306D1 (de)	1998-02-27	2010-06-10	Novo Nordisk As	Abkömmlinge von glp-1 analogen
WO1999047160A1 (en)	1998-03-13	1999-09-23	Novo Nordisk A/S	Stabilized aqueous peptide solutions
AU3087599A (en)	1998-03-19	1999-10-11	Bionebraska, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
DE19813802A1 (de)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
WO1999053064A2 (en)	1998-04-13	1999-10-21	Modex Therapeutiques, S.A.	Methods of delivering glp-1
CA2270320A1 (en)	1998-04-28	1999-10-28	Patricia Lee Brubaker	Novel microsphere composition
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
CN1119352C (zh)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	人血清白蛋白在毕赤酵母中的表达与纯化
ES2172288T3 (es)	1998-05-15	2002-09-16	Schering Corp	Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
CZ294848B6 (cs)	1998-06-12	2005-03-16	Amylin Pharmaceuticals, Inc.	Glukagonu podobný peptid-1 zlepšuje odpověď ß-buněk na glukózu u subjektů se zhoršenou tolerancí glukózy
CA2330527A1 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corporation	Erythropoietin analog-human serum albumin fusion
CN1105727C (zh)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	重组人血清白蛋白的生产方法
CA2335617C (en)	1998-06-24	2009-12-15	Emory University	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
EP1091979B1 (en)	1998-06-30	2006-09-20	Novo Nordisk A/S	Seeding crystals for the preparation of peptides or proteins
AU8508398A (en)	1998-07-15	2000-02-07	Wisconsin Alumni Research Foundation	Treatment of diabetes with synthetic beta cells
DE69911975T2 (de)	1998-07-31	2004-09-09	Novo Nordisk A/S	In-vitro stimulation von beta zellen vermehrung
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
DE69941510D1 (de)	1998-08-10	2009-11-19	Us Gov Nat Inst Health	Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
CZ2001690A3 (cs)	1998-08-28	2002-04-17	Eli Lilly And Company	Způsob podávání inzulinotropních peptidů
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6290987B1 (en)	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CA2345382A1 (en)	1998-10-16	2000-04-27	Immunex Corporation	Inhibitors of platelet activation and recruitment
ES2283139T5 (es)	1998-10-23	2018-03-05	Amgen Inc.	Métodos y composiciones para la prevención y tratamiento de la anemia
CN1325443A (zh)	1998-10-30	2001-12-05	诺沃奇梅兹有限公司	具有减弱的变应原性的糖基化蛋白
WO2000032772A2 (en)	1998-11-30	2000-06-08	Eli Lilly And Company	Erythropoietic compounds
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6312665B1 (en)	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
DK1140148T3 (da)	1998-12-22	2006-01-30	Lilly Co Eli	Lagerholdbar formulering af glucagon-agtigt peptid-1
US20030187196A1 (en) *	1998-12-30	2003-10-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
WO2000061625A1 (en)	1999-04-09	2000-10-19	Human Genome Sciences, Inc.	48 human secreted proteins
WO2001077137A1 (en) *	2000-04-12	2001-10-18	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2000062759A1 (en)	1999-04-16	2000-10-26	Novo Nordisk A/S	Dry, mouldable drug formulation
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
DE19921537A1 (de)	1999-05-11	2000-11-23	Dieter Hoersch	Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
CN1361793A (zh)	1999-05-19	2002-07-31	利思进药品公司	干扰素－α蛋白作为Fc融合蛋白的表达和运输
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
WO2000078333A2 (en)	1999-06-21	2000-12-28	Eli Lilly And Company	Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
JO2291B1 (en)	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
WO2001005826A2 (en)	1999-07-19	2001-01-25	Gpc Biotech Inc.	Chimeric polypeptides of serum albumin and uses related thereto
US20020048571A1 (en) *	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
EP1203005A4 (en)	1999-08-17	2004-11-24	Human Genome Sciences Inc	25 HUMAN SECRETED PROTEINS
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
TWI260321B (en)	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
BR0014945A (pt)	1999-10-21	2004-08-31	Monsanto Co	Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
AU1226901A (en)	1999-10-22	2001-05-08	Amgen, Inc.	Biodegradable microparticles with novel erythropoietin stimulating protein
DE60037535D1 (de)	1999-11-03	2008-01-31	Novo Nordisk As	Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
CA2324801A1 (en)	1999-11-10	2001-05-10	Andrew Gordon Swick	Use of apo b secretion/mtp inhibitors and anti-obesity agents
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
JP2003514552A (ja)	1999-11-12	2003-04-22	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	改善された性質を有するエリトロポエチンの形態
US20010046489A1 (en)	1999-12-06	2001-11-29	Habener Joel E.	Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20020025306A1 (en)	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (en)	2000-01-18	2003-01-02	Pfizer Products Inc.	Uses of agrp-melanocortin receptor binding modulating compounds
JP2003523366A (ja)	2000-01-27	2003-08-05	イーライ・リリー・アンド・カンパニー	グルカゴン様ペプチド１化合物の可溶化方法
AU2001228327A1 (en)	2000-01-31	2001-08-14	Novo-Nordisk A/S	Crystallisation of a glp-1 analogue
AU2001252201A1 (en)	2000-03-14	2001-09-24	Amylin Pharmaceuticals, Inc.	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20050100991A1 (en)	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
DK1274728T3 (da)	2000-04-21	2008-09-01	Amgen Inc	Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
IL142707A0 (en)	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
MXPA02011303A (es) *	2000-05-15	2003-04-25	Hoffmann La Roche	Nueva composicion farmaceutica.
WO2001087322A2 (en)	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
JP4716641B2 (ja)	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
JP5161412B2 (ja)	2000-09-18	2013-03-13	サノス・バイオサイエンス・アクティーゼルスカブ	Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002221222A1 (en)	2000-12-04	2002-06-18	Biovitrum Ab	Novel method and use
BR0116024A (pt)	2000-12-07	2005-12-13	Lilly Co Eli	Proteìna de fusão heteróloga e uso da mesma
EP1351984A2 (en)	2000-12-13	2003-10-15	Eli Lilly And Company	Amidated glucagon-like peptide-1
US7259233B2 (en)	2000-12-13	2007-08-21	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
KR100399337B1 (ko)	2001-02-07	2003-09-26	드림바이오젠 주식회사	단백질의 무세포 번역후수식법
EP1949908A1 (en)	2001-03-07	2008-07-30	Novo Nordisk A/S	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020169128A1 (en)	2001-04-09	2002-11-14	Geroge Sigounas	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20050054051A1 (en)	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en)	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002085406A1 (en)	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
EP1401477A4 (en)	2001-05-25	2005-02-02	Human Genome Sciences	CHIMIOKINE BETA-1 HYBRID PROTEINS
AU2002308706A1 (en)	2001-06-01	2002-12-16	Eli Lilly And Company	Glp-1 formulations with protracted time action
WO2003003971A2 (fr)	2001-06-20	2003-01-16	Merck Sante	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
ATE382057T1 (de)	2001-06-28	2008-01-15	Novo Nordisk As	Stabile formulierung von modifiziertem glp-1
DE60228972D1 (de)	2001-07-31	2008-10-30	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2002327430A1 (en)	2001-08-08	2003-02-24	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
US7186797B2 (en)	2001-08-10	2007-03-06	Epix Pharmaceuticals, Inc.	Polypeptide conjugates with extended circulating half-lives
WO2003018516A2 (en)	2001-08-23	2003-03-06	Eli Lilly And Company	Glucagon-like peptide-1 analogs
WO2003030821A2 (en)	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2466024T3 (es) *	2001-10-10	2014-06-09	Ratiopharm Gmbh	Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
EP2277889B1 (en)	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
CA2484556A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
WO2003054182A2 (en)	2001-12-21	2003-07-03	Nexia Biotechnologies, Inc.	Production of butyrylcholinesterases in transgenic mammals
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
AU2003210806A1 (en)	2002-03-05	2003-09-22	Eli Lilly And Company	Heterologous g-csf fusion proteins
DE60336555D1 (de) *	2002-06-21	2011-05-12	Novo Nordisk Healthcare Ag	Pegylierte glykoformen von faktor vii
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
EP1594530A4 (en) *	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
DK1596888T3 (da) *	2003-02-27	2012-03-26	Baxter Int	Fremgangsmåde til den validerbare inaktivering af patogener i et biologisk fluidum ved bestråling
ATE525395T1 (de)	2003-06-12	2011-10-15	Lilly Co Eli	Fusions proteine von glp-1-analoga
CA2554089C (en)	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
EP1924596A4 (en)	2005-08-12	2009-07-29	Human Genome Sciences Inc	ALBUM INFUSION PROTEINS
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
CA2562249A1 (en)	2005-10-20	2007-04-20	University Of Ottawa Heart Institute	Anf analogue
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2838833A1 (en) *	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof

2001
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Ceased
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Ceased
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en not_active Ceased
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en not_active Ceased
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Ceased
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Ceased
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en not_active Ceased
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
2005
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
2016
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001077137A9 (en)	2002-05-02
FR16C0043I1 (ru)	2016-12-09
WO2001077137A1 (en)	2001-10-18
EP2267026A1 (en)	2010-12-29
EP1276756A1 (en)	2003-01-22
EP1276856A4 (en)	2004-06-09
CA2747325A1 (en)	2001-10-25
WO2001079271A9 (en)	2002-02-28
JP2003530852A (ja)	2003-10-21
US20080269126A1 (en)	2008-10-30
WO2001079258A1 (en)	2001-10-25
FR16C0043I2 (fr)	2020-04-10
EP1803730A1 (en)	2007-07-04
US20030199043A1 (en)	2003-10-23
EP2357008A1 (en)	2011-08-17
US20120252732A1 (en)	2012-10-04
JP2004506407A (ja)	2004-03-04
EP1274719A2 (en)	2003-01-15
EP1278544A4 (en)	2004-08-18
EP1832599A2 (en)	2007-09-12
EP1274720A1 (en)	2003-01-15
AU2001261024A1 (en)	2001-10-30
US20080261877A1 (en)	2008-10-23
US20030219875A1 (en)	2003-11-27
ES2484966T3 (es)	2014-08-12
ES2529300T3 (es)	2015-02-18
US20120141415A1 (en)	2012-06-07
WO2001079442A2 (en)	2001-10-25
EP2275557A1 (en)	2011-01-19
US20140004095A1 (en)	2014-01-02
US6905688B2 (en)	2005-06-14
EP2216409A1 (en)	2010-08-11
CA2405563A1 (en)	2001-10-25
US20040010134A1 (en)	2004-01-15
EP2236152A1 (en)	2010-10-06
US10080785B2 (en)	2018-09-25
AU2001259063A1 (en)	2001-10-30
EP1278544A2 (en)	2003-01-29
EP1276756A4 (en)	2004-06-09
EP2067488A1 (en)	2009-06-10
AU2001274809A1 (en)	2001-10-30
US20080267962A1 (en)	2008-10-30
WO2001079442A3 (en)	2002-06-06
EP1276849A4 (en)	2004-06-09
EP1278767A4 (en)	2003-11-12
US20030171267A1 (en)	2003-09-11
CA2405912A1 (en)	2001-10-18
JP2003530839A (ja)	2003-10-21
US20120141449A1 (en)	2012-06-07
JP2003531590A (ja)	2003-10-28
US9775888B2 (en)	2017-10-03
US20180200346A1 (en)	2018-07-19
CA2405701A1 (en)	2001-10-25
WO2001079258A9 (en)	2002-02-28
US20050266533A1 (en)	2005-12-01
EP2216409B1 (en)	2014-12-03
EP1983055A1 (en)	2008-10-22
EP2295456A1 (en)	2011-03-16
US20040171123A1 (en)	2004-09-02
WO2001079480A1 (en)	2001-10-25
US7507414B2 (en)	2009-03-24
JP2003530838A (ja)	2003-10-21
CA2405709A1 (en)	2001-10-25
EP2298355A2 (en)	2011-03-23
AU2001264563A1 (en)	2001-10-30
US20030125247A1 (en)	2003-07-03
EP1832599A3 (en)	2007-11-21
EP1274720A4 (en)	2004-08-18
US7482013B2 (en)	2009-01-27
AU2001259066A1 (en)	2001-10-30
WO2001079444A2 (en)	2001-10-25
JP2003530846A (ja)	2003-10-21
US20090285816A9 (en)	2009-11-19
US20100189686A1 (en)	2010-07-29
US20070287173A9 (en)	2007-12-13
US20080269128A1 (en)	2008-10-30
US8946156B2 (en)	2015-02-03
AU2001266557A1 (en)	2001-10-23
CA2405525A1 (en)	2001-10-25
US20080269127A1 (en)	2008-10-30
CA2405550A1 (en)	2001-10-25
US20110280830A9 (en)	2011-11-17
WO2001079443A2 (en)	2001-10-25
EP1274719A4 (en)	2004-05-19
US20050266532A1 (en)	2005-12-01
EP1278767A1 (en)	2003-01-29
EP2298355A3 (en)	2011-06-29
JP2003530847A (ja)	2003-10-21
CA2405557A1 (en)	2001-10-25
US6926898B2 (en)	2005-08-09
US20080269125A1 (en)	2008-10-30
JP2014057589A (ja)	2014-04-03
EP2206720A1 (en)	2010-07-14
EP2311872A1 (en)	2011-04-20
WO2001079444A3 (en)	2002-05-23
US9821039B2 (en)	2017-11-21
CA2405557C (en)	2013-09-24
EP2213743A1 (en)	2010-08-04
WO2001079443A3 (en)	2002-02-21
WO2001079271A1 (en)	2001-10-25
EP1276849A2 (en)	2003-01-22
US6994857B2 (en)	2006-02-07
WO2001079480A9 (en)	2003-09-18
US20130266553A1 (en)	2013-10-10
DK2216409T3 (en)	2015-01-05
US20080131399A1 (en)	2008-06-05
JP2011217750A (ja)	2011-11-04
AU2001262942A1 (en)	2001-10-30
US9849162B2 (en)	2017-12-26
EP1276856A1 (en)	2003-01-22
EP2236152B1 (en)	2014-06-04
US20140010798A1 (en)	2014-01-09
DK2236152T3 (da)	2014-07-07
US7785599B2 (en)	2010-08-31

Publication	Publication Date	Title
BE2017C009I2 (ru)	2017-09-22
BE2014C019I2 (ru)	2021-01-29
BE2014C009I2 (ru)	2021-02-04
BE2010C019I2 (ru)	2020-08-20
BRPI0112928B8 (ru)	2021-05-25
BRPI0110940B8 (ru)	2021-05-25
CN300955183S (zh)	2009-07-08	连接件
IN189757B (ru)	2003-04-19
BRPI0000763B8 (ru)	2021-06-22
CN3139842S (ru)	2000-02-23
CN3141005S (ru)	2000-03-08
AU2000278560A8 (ru)	2001-12-06
AU2000276986A8 (ru)	2002-06-27
AU2000276780A8 (ru)	2001-07-12
AU2000271150A8 (ru)	2002-06-13
AU2000256695A8 (ru)	2002-05-02
CN3133324S (ru)	2000-01-05
CN3133951S (ru)	2000-01-05
CN3134893S (ru)	2000-01-19
CN3147763S (ru)	2000-05-10
CN3135789S (ru)	2000-01-26
CN3136653S (ru)	2000-02-02
CN3136721S (ru)	2000-02-02
CN3137256S (ru)	2000-02-02
CN3135469S (ru)	2000-01-19